IMO, there a a lot of weak hands on the LDX thread who fail to understand the LDX business case, and therefore fail to see the significant potential of LDX, including the market advantage which LDX has been able to leverage by positioning itself as a specialist in the rapid point of care diagnostic sector with a particular focus on tackling microbial resistance to antibiotics (AMR).
Just two weeks ago, world leader gathered in New York to commit to decisive action on combating AMR, including by providing funding and other forms of material support to this effort.
IMO, there is good reason to have a bullish outlook on LDX, and with 63.09% of the company already held by the top 20 shareholders (IMO a very tightly held register), it seems that those who could be considered "smart money" also agree with a bullish LDX outlook.
Add to My Watchlist
What is My Watchlist?
